Alligator Bioscience issues 187,795,097 warrants to Fenja Capital with 5% dilution potential

By Public Technologies
  • Alligator Bioscience issued 187,795,097 warrants series 2026/2031 to Fenja Capital, free of charge, tied to a renegotiated loan.
  • Warrants carry a 5% dilution based on shares outstanding immediately after the completed rights issue and compensation issue.
  • Exercise runs from registration with the Swedish Companies Registration Office through Oct. 31, 2031 at SEK 0.028 per share.
  • Full exercise would add 187,795,097 shares, lifting shares outstanding to 3,755,901,945, for up to about SEK 5 million proceeds.
  • Earlier warrants series 2025/2030 issued to Fenja Capital will be cancelled; the new warrants will not be admitted to trading.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alligator Bioscience AB published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.